Pharmaceutical Commerce
OCTOBER 31, 2024
Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.
Bio Pharma Dive
OCTOBER 31, 2024
In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid in a Phase 3 trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
OCTOBER 31, 2024
Paragonix Technologies, an innovator in organ transport and preservation solutions, has received US Food and Drug Administration (FDA) 510(k) clearance for its KidneyVault Portable Renal Perfusion System. This clearance allows the KidneyVault system to be used in the US to improve the quality of kidney preservation and ultimately improve outcomes for patients undergoing kidney transplants.
Bio Pharma Dive
OCTOBER 31, 2024
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding an IPO, its CEO said.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
OCTOBER 31, 2024
Reeves' budget promised investment for innovation and R&D with a view to "harnessing the full potential of the UK’s science base”.
Bio Pharma Dive
OCTOBER 31, 2024
The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 31, 2024
Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on former director Jeff Shuren’s leadership.
Pharma Times
OCTOBER 31, 2024
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
Bio Pharma Dive
OCTOBER 31, 2024
The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.
Pharmaceutical Technology
OCTOBER 31, 2024
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
Pharmaceutical Technology
OCTOBER 31, 2024
The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was terminated.
pharmaphorum
OCTOBER 31, 2024
Effective language training for healthcare teams within the NHS is crucial for providing quality care and communication with diverse patient populations. Learn why it is essential for healthcare professionals.
Pharmaceutical Technology
OCTOBER 31, 2024
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.
pharmaphorum
OCTOBER 31, 2024
Compass Pathways will cut its headcount by 30% as it defers phase 3 readouts for its psychedelic therapy for treatment-resistant depression.
XTalks
OCTOBER 31, 2024
In this episode, Ayesha spoke with Robert Perkins, MD, Vice President, US Medical Affairs/Renal at Bayer who spoke about recent advancements in the heart failure (HF) treatment landscape. This includes new Phase III trial data for Kerendia (finerenone) in patients with heart failure that was presented recently at this year’s European Society of Cardiology (ESC) Congress 2024.
pharmaphorum
OCTOBER 31, 2024
The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.
Fierce Pharma
OCTOBER 31, 2024
With U.S. | With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, however, is that while sales from Eylea HD increased by 29% sequentially, this didn't translate to a similar bump in overall U.S. revenue for the Eylea family of eye medications.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 31, 2024
Our latest round-up of financings in the biotech sector features Alpha-9 Oncology, Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Therapeutics.
Fierce Pharma
OCTOBER 31, 2024
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.
pharmaphorum
OCTOBER 31, 2024
Lexeo reveals "promising" early data for gene therapy for APOE4-associated Alzheimer's, but shares in the biotech fall.
Outsourcing Pharma
OCTOBER 31, 2024
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
pharmaphorum
OCTOBER 31, 2024
Septerna's protracted IPO on the Nasdaq has finally reached its conclusion, with the final amount raised by the GPCR-focused biotech above $331m
Outsourcing Pharma
OCTOBER 31, 2024
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
Drug Discovery World podcast
OCTOBER 31, 2024
This is the latest episode of the free DDW narrated podcast, titled “How to streamline regulatory approval”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Quicker time to regulatory submission through improved data management and The three key stages to a successful specialty drug launch. In the first article, Ken Forman, Senior Director of Product Strategy, IDBS explains how robust digital workflows can reduce errors and time to compile dat
Fierce Pharma
OCTOBER 31, 2024
Author: Harietta Eleftherochorinou, Vice President, AI Strategy and Operations, IQVIA | We are entering a new era of AI in life sciences, where generative AI, conversational AI and AI agents are transforming day-to-day operations.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Intouch Solutions
OCTOBER 31, 2024
At EVERSANA and EVERSANA INTOUCH, we are committed to fostering an environment where every individual’s unique abilities and perspectives are not only recognized but celebrated. This October, in honor of National Disability Employment Awareness Month (NDEAM), we dedicated ourselves to highlighting the significant contributions of employees with disabilities and reinforcing our commitment to inclusive employment practices.
Pharmaceutical Commerce
OCTOBER 31, 2024
The latest news for pharma industry insiders.
Fierce Pharma
OCTOBER 31, 2024
AstraZeneca executives past and present are under investigation in China. GSK is paying $300 million upfront to obtain a T-cell engager to develop for autoimmune diseases. | AstraZeneca executives past and present are under investigation in China. GSK is paying $300 million upfront to obtain a T-cell engager to develop for autoimmune diseases. Takeda has hit a setback with its orexin receptor 2 agonist danavorexton.
BioPharma Reporter
OCTOBER 31, 2024
The expansion of its QC microbiology lab meets the growing demand for quality testing.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
59 
Let's personalize your content